Patents Assigned to Guardant Health, Inc.
  • Patent number: 12291751
    Abstract: Provided herein are methods for detecting tumor mutational burden (TMB) in subjects. In one aspect, the methods include determining observed mutational counts from sequence information obtained from nucleic acids in samples from the subjects and determining a tumor fraction and/or a coverage of the nucleic acids to generate sequencing parameters. The methods also include determining an expected mutational fraction and/or an expected distribution of the expected mutational fraction given the sequencing parameters to generate an expected result, and adjusting the observed mutational count given the expected result to generate an adjusted result, thereby detecting the TMB in the subject. Other aspects are directed to methods of selecting customized therapies for treating cancer in subjects, and methods of treating cancer in subjects. Yet other aspects include related systems and computer readable media used to detect TMB in subjects.
    Type: Grant
    Filed: July 28, 2021
    Date of Patent: May 6, 2025
    Assignee: Guardant Health, Inc.
    Inventors: Katie Julia Quinn, Elena Helman, Darya Chudova
  • Patent number: 12286672
    Abstract: Disclosed herein in are methods and systems for determining genetic variants (e.g., copy number variation) in a polynucleotide sample. A method for determining copy number variations includes tagging double-stranded polynucleotides with duplex tags, sequencing polynucleotides from the sample and estimating total number of polynucleotides mapping to selected genetic loci. The estimate of total number of polynucleotides can involve estimating the number of double-stranded polynucleotides in the original sample for which no sequence reads are generated. This number can be generated using the number of polynucleotides for which reads for both complementary strands are detected and reads for which only one of the two complementary strands is detected.
    Type: Grant
    Filed: August 23, 2024
    Date of Patent: April 29, 2025
    Assignee: Guardant Health, Inc.
    Inventors: AmirAli Talasaz, Helmy Eltoukhy, Stefanie Ann Ward Mortimer
  • Patent number: 12287759
    Abstract: A data processing architecture controls data processing arbitration in a high performance computing system that includes one or more premises. Individual premises can include one or more server computers executing an instance of a local file system and including one or more temporary data storage devices. Individual instances of the local file system can access files stored in objects of a primary data store. Individual objects of the primary data store can be accessed using a common identifier indicating a storage location of the individual objects in the primary data store.
    Type: Grant
    Filed: October 25, 2024
    Date of Patent: April 29, 2025
    Assignee: Guardant Health, Inc.
    Inventors: William Patrick Baird, Mikhail Zhagrov, Alexander David Younts, Varsha Kohirkar, Kumud Kalia
  • Patent number: 12288598
    Abstract: The disclosure relates to computer technology for precision diagnosis of various states of genetic material such as a gene sequenced from cell-free DNA in a sample. The state may include a somatic homozygous deletion, a somatic heterozygous deletion, a copy number variation, or other states. A computer system may generate competing probabilistic models that each output a probability that the genetic material is in a certain state. Each model may be trained on a training sample set to output a probability that the genetic material is in a respective state. In some embodiments, the computer system may use various probabilistic distributions to generate the models. For example, the computer system may use a beta-binomial distribution, a binomial distribution, a normal (also referred to as “Gaussian”) distribution, or other type of probabilistic modeling techniques.
    Type: Grant
    Filed: July 6, 2023
    Date of Patent: April 29, 2025
    Assignee: Guardant Health, Inc.
    Inventors: Catalin Barbacioru, Marcin Sikora, Darya Chudova
  • Patent number: 12281354
    Abstract: The present disclosure provides a method for monitoring residual disease in a subject. Generally, the method comprises determining a frequency of cancer mutations from a first sample obtained from a tumor biopsy from the subject; determining a frequency of the cancer mutations discovered in the first sample from a second sample comprising cell-free deoxyribonucleic acid (cfDNA) molecules that is obtained from the subject after the subject has undergone a course of treatment for cancer; and determining a presence or absence of cancer in the subject based on an analysis of the frequency of the cancer mutations from sequence data from the second sample, wherein adapters are ligated to at least 20% of the cfDNA molecules using more than a 10× molar excess of adapters relative to the cfDNA molecules in the population of cfDNA molecules.
    Type: Grant
    Filed: May 29, 2024
    Date of Patent: April 22, 2025
    Assignee: Guardant Health, Inc.
    Inventors: AmirAli Talasaz, Stefanie Ann Ward Mortimer
  • Patent number: 12258626
    Abstract: Disclosed herein in are methods and systems for determining genetic variants (e.g., copy number variation) in a polynucleotide sample. A method for determining copy number variations includes tagging double-stranded polynucleotides with duplex tags, sequencing polynucleotides from the sample and estimating total number of polynucleotides mapping to selected genetic loci. The estimate of total number of polynucleotides can involve estimating the number of double-stranded polynucleotides in the original sample for which no sequence reads are generated. This number can be generated using the number of polynucleotides for which reads for both complementary strands are detected and reads for which only one of the two complementary strands is detected.
    Type: Grant
    Filed: August 22, 2024
    Date of Patent: March 25, 2025
    Assignee: Guardant Health, Inc.
    Inventors: Amirali Talasaz, Helmy Eltoukhy, Stefanie Ann Ward Mortimer
  • Patent number: 12252749
    Abstract: The present disclosure provides a system and method for the detection of rare mutations and copy number variations in cell free polynucleotides. Generally, the systems and methods comprise sample preparation, or the extraction and isolation of cell free polynucleotide sequences from a bodily fluid; subsequent sequencing of cell free polynucleotides by techniques known in the art; and application of bioinformatics tools to detect rare mutations and copy number variations as compared to a reference. The systems and methods also may contain a database or collection of different rare mutations or copy number variation profiles of different diseases, to be used as additional references in aiding detection of rare mutations, copy number variation profiling or general genetic profiling of a disease.
    Type: Grant
    Filed: January 30, 2024
    Date of Patent: March 18, 2025
    Assignee: Guardant Health, Inc.
    Inventor: AmirAli Talasaz
  • Patent number: 12241126
    Abstract: Provided herein are methods of generating a homologous recombination repair deficiency (HRD) score, determining a reference HRD score, determining a HRD status of a test subject having one or more cancer types, and/or treating a disease based on HRD status. Additional methods as well as related systems, apparatuses, and computer readable media are also provided.
    Type: Grant
    Filed: May 14, 2021
    Date of Patent: March 4, 2025
    Assignee: Guardant Health, Inc.
    Inventors: Jennifer Yen, Elena Helman, Arielle Yablonovitch
  • Patent number: 12241128
    Abstract: Disclosed herein are methods, compositions, and devices for use in the early detection of cancer. The methods include preparing cell-free nucleic acid molecules from a subject for sequencing, sequencing a panel of regions in the cell-free nucleic acid molecules, and detecting one or more markers that are indicative of a cancer.
    Type: Grant
    Filed: February 14, 2024
    Date of Patent: March 4, 2025
    Assignee: Guardant Health, Inc.
    Inventors: Stefanie Ann Ward Mortimer, Amirali Talasaz, Darya Chudova, Helmy Eltoukhy
  • Patent number: 12234518
    Abstract: The present disclosure provides compositions and methods related to analyzing DNA, such as cell-free DNA. In some embodiments, the cell-free DNA is from a subject having or suspected of having cancer and/or the cell-free DNA includes DNA from cancer cells. In some embodiments, the DNA is partitioned into a first subsample and a second subsample, wherein the first subsample comprises DNA with a nucleotide modification (e.g., a cytosine modification) in a greater proportion than the second subsample, and the second subsample is subjected to a procedure that affects a first nucleobase in the DNA differently from a second nucleobase in the DNA of the first subsample, and the DNA is sequenced in a manner that distinguishes the first nucleobase from the second nucleobase in the DNA of the second subsample.
    Type: Grant
    Filed: October 21, 2021
    Date of Patent: February 25, 2025
    Assignee: Guardant Health, Inc.
    Inventors: Andrew Kennedy, William J. Greenleaf
  • Publication number: 20240352449
    Abstract: Disclosed herein are methods for isolating DNA, such as cell-free DNA (cfDNA) or DNA from a tissue sample, e.g., in which the DNA is partitioned into hypermethylated and hypomethylated partitions. After differential tagging of the partitions, portions of the hypomethylated partition are pooled with the hypermethylated partition or pooled separately. Epigenetic and sequence-variable target regions are captured from the pool comprising DNA from the hypermethylated and hypomethylated partitions, and sequence-variable target regions are captured from the pool comprising DNA from the hypomethylated partition. This approach can reduce costs and/or bandwidth by limiting sequencing of epigenetic target regions from the hypomethylated partition, which may be less informative than other DNA.
    Type: Application
    Filed: February 27, 2024
    Publication date: October 24, 2024
    Applicant: GUARDANT HEALTH INC.
    Inventors: Ariel JAIMOVICH, Sven Jeffrey DUENWALD, Peter Vilem GRAUMAN, Yupeng HE, Charbel Said EID, Haley Dara AXELROD
  • Patent number: 12116640
    Abstract: Disclosed herein are methods, compositions, and devices for use in the early detection of cancer. The methods include preparing cell-free nucleic acid molecules from a subject for sequencing, sequencing a panel of regions in the cell-free nucleic acid molecules, and detecting one or more markers that are indicative of a cancer.
    Type: Grant
    Filed: February 8, 2024
    Date of Patent: October 15, 2024
    Assignee: Guardant Health, Inc.
    Inventors: Stefanie Ann Ward Mortimer, AmirAli Talasaz, Darya Chudova, Helmy Eltoukhy
  • Patent number: 12116624
    Abstract: The present disclosure provides a system and method for the detection of rare mutations and copy number variations in cell free polynucleotides. Generally, the systems and methods comprise sample preparation, or the extraction and isolation of cell free polynucleotide sequences from a bodily fluid; subsequent sequencing of cell free polynucleotides by techniques known in the art; and application of bioinformatics tools to detect rare mutations and copy number variations as compared to a reference. The systems and methods also may contain a database or collection of different rare mutations or copy number variation profiles of different diseases, to be used as additional references in aiding detection of rare mutations, copy number variation profiling or general genetic profiling of a disease.
    Type: Grant
    Filed: December 11, 2023
    Date of Patent: October 15, 2024
    Assignee: Guardant Health, Inc.
    Inventors: AmirAli Talasaz, Stefanie Ann Ward Mortimer
  • Patent number: 12110560
    Abstract: The present disclosure provides a method for monitoring residual disease in a subject. Generally, the method comprises determining a frequency of cancer mutations from a first sample obtained from a tumor biopsy from the subject; determining a frequency of the cancer mutations discovered in the first sample from a second sample comprising cell-free deoxyribonucleic acid (cfDNA) molecules that is obtained from the subject after the subject has undergone a course of treatment for cancer; and determining a presence or absence of cancer in the subject based on an analysis of the frequency of the cancer mutations from sequence data from the second sample.
    Type: Grant
    Filed: March 4, 2024
    Date of Patent: October 8, 2024
    Assignee: Guardant Health, Inc.
    Inventor: AmirAli Talasaz
  • Patent number: 12106825
    Abstract: The disclosure relates to computer technology for precision diagnosis of various states of genetic material such as a gene sequenced from cell-free DNA in a sample. The state may include a somatic homozygous deletion, a somatic heterozygous deletion, a copy number variation, or other states. A computer system may generate competing probabilistic models that each output a probability that the genetic material is in a certain state. Each model may be trained on a training sample set to output a probability that the genetic material is in a respective state. In some embodiments, the computer system may use various probabilistic distributions to generate the models. For example, the computer system may use a beta-binomial distribution, a binomial distribution, a normal (also referred to as “Gaussian”) distribution, or other type of probabilistic modeling techniques.
    Type: Grant
    Filed: September 18, 2023
    Date of Patent: October 1, 2024
    Assignee: Guardant Health, Inc.
    Inventors: Catalin Barbacioru, Marcin Sikora, Darya Chudova
  • Patent number: 12098421
    Abstract: Disclosed herein in are methods and systems for determining genetic variants (e.g., copy number variation) in a polynucleotide sample. A method for determining copy number variations includes tagging double-stranded polynucleotides with duplex tags, sequencing polynucleotides from the sample and estimating total number of polynucleotides mapping to selected genetic loci. The estimate of total number of polynucleotides can involve estimating the number of double-stranded polynucleotides in the original sample for which no sequence reads are generated. This number can be generated using the number of polynucleotides for which reads for both complementary strands are detected and reads for which only one of the two complementary strands is detected.
    Type: Grant
    Filed: May 15, 2023
    Date of Patent: September 24, 2024
    Assignee: Guardant Health, Inc.
    Inventors: Amirali Talasaz, Helmy Eltoukhy, Stefanie Ann Ward Mortimer
  • Patent number: 12100482
    Abstract: The present disclosure provides a method for enriching for multiple genomic regions using a first bait set that selectively hybridizes to a first set of genomic regions of a nucleic acid sample and a second bait set that selectively hybridizes to a second set of genomic regions of the nucleic acid sample. These bait set panels can selectively enrich for one or more nucleosome-associated regions of a genome, said nucleosome-associated regions comprising genomic regions having one or more genomic base positions with differential nucleosomal occupancy, wherein the differential nucleosomal occupancy is characteristic of a cell or tissue type of origin or disease state.
    Type: Grant
    Filed: November 7, 2023
    Date of Patent: September 24, 2024
    Assignee: Guardant Health, Inc.
    Inventors: Darya Chudova, Helmy Eltoukhy, Stefanie Ann Ward Mortimer, Diana Abdueva
  • Patent number: 12098422
    Abstract: Disclosed herein in are methods and systems for determining genetic variants (e.g., copy number variation) in a polynucleotide sample. A method for determining copy number variations includes tagging double-stranded polynucleotides with duplex tags, sequencing polynucleotides from the sample and estimating total number of polynucleotides mapping to selected genetic loci. The estimate of total number of polynucleotides can involve estimating the number of double-stranded polynucleotides in the original sample for which no sequence reads are generated. This number can be generated using the number of polynucleotides for which reads for both complementary strands are detected and reads for which only one of the two complementary strands is detected.
    Type: Grant
    Filed: December 13, 2023
    Date of Patent: September 24, 2024
    Assignee: Guardant Health, Inc.
    Inventors: AmirAli Talasaz, Helmy Eltoukhy, Stefanie Ann Ward Mortimer
  • Patent number: 12094573
    Abstract: The present disclosure provides a method for enriching for multiple genomic regions using a first bait set that selectively hybridizes to a first set of genomic regions of a nucleic acid sample and a second bait set that selectively hybridizes to a second set of genomic regions of the nucleic acid sample. These bait set panels can selectively enrich for one or more nucleosome-associated regions of a genome, said nucleosome-associated regions comprising genomic regions having one or more genomic base positions with differential nucleosomal occupancy, wherein the differential nucleosomal occupancy is characteristic of a cell or tissue type of origin or disease state.
    Type: Grant
    Filed: November 10, 2023
    Date of Patent: September 17, 2024
    Assignee: Guardant Health, Inc.
    Inventors: Darya Chudova, Helmy Eltoukhy, Stefanie Ann Ward Mortimer, Diana Abdueva
  • Patent number: 12054774
    Abstract: Disclosed herein in are methods and systems for determining genetic variants (e.g., copy number variation) in a polynucleotide sample. A method for determining copy number variations includes tagging double-stranded polynucleotides with duplex tags, sequencing polynucleotides from the sample and estimating total number of polynucleotides mapping to selected genetic loci. The estimate of total number of polynucleotides can involve estimating the number of double-stranded polynucleotides in the original sample for which no sequence reads are generated. This number can be generated using the number of polynucleotides for which reads for both complementary strands are detected and reads for which only one of the two complementary strands is detected.
    Type: Grant
    Filed: May 12, 2023
    Date of Patent: August 6, 2024
    Assignee: Guardant Health, Inc.
    Inventors: AmirAli Talasaz, Helmy Eltoukhy, Stefanie Ann Ward Mortimer